As Beovu Debut Nears, Novartis Set to Push Longer Dosing Interval, Pivotal Data in Battle against Eylea

Novartis’ blockbuster hopeful VEGF inhibitor Beovu (brolucizumab) is soon to hit the fridges of ophthalmic clinics in Japan following its listing earlier this week, pitting itself against market leader Eylea (aflibercept). The Swiss giant is poised to pitch its longer...read more